State litigation guide · Texas

Tepezza Hearing Loss Lawsuit in Texas

Time limits apply in Texas. Find out if you still qualify.

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

People's Justice Research TeamUpdated July 25, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Statute of limitations — Texas

Texas Civil Practice and Remedies Code § 16.003 provides a 2-year statute of limitations for personal injury claims. The discovery rule applies for pharmaceutical injuries — the limitations period begins when the plaintiff discovers or reasonably should have discovered the connection between Tepezza and hearing loss. Texas also has a 15-year statute of repose for product liability claims under § 16.012.

2 years from discovery of Tepezza-related hearing injury

Filing venue

Where to File in Texas

Federal Tepezza cases filed in Texas are transferred to the MDL in the Northern District of Illinois (MDL No. 3079). Texas state court claims may proceed separately in Harris County (Houston), Dallas County, or Bexar County (San Antonio) district courts. Texas applies a Daubert-style reliability standard for expert testimony under Texas Rule of Evidence 702, which can present higher hurdles for causation experts compared to some other states. However, the strong post-market evidence linking Tepezza to hearing damage supports causation in both state and federal courts.

Texas data

Exposure in Texas

Texas population — second-largest Tepezza patient pool in the nation, with major treatment centers in Houston, Dallas, and San Antonio

30.5 million

Source: U.S. Census Bureau 2024

Hearing impairment rate reported in Tepezza clinical trials (vs. 0% on placebo) — post-market data shows rates up to 65%, roughly 6.5 times higher

10%

Source: FDA-approved prescribing information

Date FDA required Horizon Therapeutics to update Tepezza label to warn of severe and possibly irreversible hearing impairment

July 2023

Source: U.S. Food and Drug Administration

Keep reading